预约演示

Biosimilars making inroads into Humira sales, but docs still cautious on switching: Spherix

2023-09-19

上市批准生物类似药专利到期

Humira sales are set to be eroded by a tsunami of new biosimilars, with Amgen's Amjevita currently leading the pack.

Humiraear, there has been an influx of biosimilars aiming to capture a sAmgenof Amjevitabillion annual revenue generated by AbbVie's mega biologic blockbuster Humira. However, these copycat biologics have yet to make a significant impact in the market.

That’s according to an analysis from Spherix Global Insights, which found a “continued erosion” of AbbVie’s Humira, also knoAbbVieadalimumab, in “favor of a growing embrace of these diverse biosimilars.”

But Spherix warns that healthcare preSpherix Global Insightsly warmed to these newcomers,” with derAbbViegists in particular showiadalimumabghest degree of stated resistance to change” and rheumatologists reporting the least actual erosion to branded Humira.

The Spherixis based on a survey of U.S. healthcare specialists, including 80 dermatologists, 83 gastroenterologists and 81 rheumatologists.

Humira is a moneymaking juggernaut, bringing in $20 billion a year for AbbVie at its peak over the past few years.

It has achieved this by expanding its sales platform since receiving itAbbVieial FDA approval in 2002. This expansion has been consistent, with the addition of increasingly lucrative indications over the years. Today, these indications encompass rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis and other autoimmune disorders.

AbbVie has, for years, been preparing for generic competition affecting its flagship drug franchise. Recently, it has reduced advertising for this medication across all its brands and shifted its focus to immunology drugs like Rinvoq and Skyrizi rheumatoid arthritisalpsoriatic arthritis Crohn's disease ulcerative colitis plaque psoriasis autoimmune disorders

AbbVie sales are, in fact, expected to slip some 37% this year, according to AbbVie’s recent financials, thanks in the most part to the new onslaught of biosimilars.Rinvoq Skyrizi

Humiraear, the introduction of Amjevita by Amgen represents a significant bioAbbVier entrant against Humira. Amjevita received FDA approval in January with the same broad labels as Humira, followed by a wave of other biosimilars in the summer.

Other prominent players includeAmjevitager Amgenheim’s Cyltezo, Sandoz’s Hyrimoz and Biocon’s Hulio aHumira aAmjevitas BioScienFDA’ Yusimry.Humira

Spherix's survey revealed that tBoehringer Ingelheimf participanSandoze aware of the Bioconsing availability ofCoherus BioSciencesb Yusimrylars. They primarily recognized Amjevita as a prominent approved adalimumab biosimilar, largely due to the Amgen name and the anticipation of its arrival over the years.

Spherix found that Cyltezo by Boehringer Ingelheim is widely preferred across specialties. This preference is attributed adalimumabque status as the sole FDA-approved biosAmjevitaith interchangeability stadalimumabntially, the FDA has indicated tAmgenhere is minimal difference between Humira and Cyltezo when switched, which should alleviate safety and efficacy concerns for doctors prescribing the drug.

Spherix also found CyltezondozBoehringer Ingelheimn’s Hulio garner “notable recognition” among dermatologists and rheumatologists, while Coherus BioSciencFDA Yusimry “enjoys higher recall rates” among gastroenterologists.FDA Humira Cyltezo

Spherix, analysts found Sandozmjevita was theBioconfamiliar among biosimilar brands launched in July, with Cytelzo in a respectable seconCoherus BioSciencesa considerable distance.

Spherix noted that one missinAmjevitat needed to boost biosimilar uptake is “clear and regular sales representative messaging,” given that it found most specialists report they do not know how to differentiate between all the new adalimumab biosimilars on the market.

Spherixing sales representative contact, Humira continues to lead the pack with the most regular and frequent sales representative visits, regardless of specialty,” the report found, while Amjevita contact rates are highest among adalimumabilars, with Amjevita messaging regularly zeroing in on comparative efficacy and cost savings/coverage.

“Of the newer launched brands, Cyltezo again has the greatest presence out of the gate, with messaging nearly always including a focus on the brand’s interchangeability status; however, theAmjevitay have yet to meet with a Boehringer Ingelheim representative,” according to the report.

The report noted that efficacy Cyltezo “top of mind” as prescribers’ leading concern for adalimumab biosimilars, followed by safety concerns and an overall lack of cost savings.Boehringer Ingelheim